Erythrodiol in Pomace Olive Oil as a Protective Agent Against Atherosclerosis

The goal of this postprandial clinical trial is to learn whether erythrodiol, a triterpene naturally present in pomace olive oil, can modulate the cell foam formation, ine of the first steps in atherosclerosis. The main questions it aims to answer are: Is erythrodiol bioavailable in humans when administered as pomace olive oil? Does acute erythrodiol intake reduce postprandial triglyceride excursions after a high-fat meal? Does erythrodiol reduce the intake of postprandial triglyceride-rich lipoproteins by macrophages? Researchers will compare participants receiving test meals enriched with different concentrations of erythrodiol (low, medium, high) to see if the intervention leads to improved postprandial metabolic and vascular responses. Participants will: Attend the research facility after an overnight fast. Consume a high-fat test meal enriched with a different doses of erythrodiol Undergo serial postprandial assessments over several hours, including: Blood sampling for lipids, glucose, inflammatory markers, and oxidative stress biomarkers Monitoring of subjective tolerability and adverse events

NCT Number	NCT07422051
Lead Sponsor	Spanish National Research Council
Conditions	Atherosclerosis Cardiovascular Disease
Enrollment	22 participants
Start Date	2026-02-21
Primary Completion	2026-06-30 (estimated)
Study Completion	2026-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-19